Information Provided By:
Fly News Breaks for April 12, 2016
CPXX
Apr 12, 2016 | 08:39 EDT
Roth Capital analyst Joseph Pantginis is positive on Celator Pharmaceuticals' Vyxeos for the treatment of acute myeloid leukemia, following "historic" Phase III data. The analyst expects Vyxeos to supplant the standard of care 7+3 therapy, with high adoption rates. Now that the program has been de-risked, the analyst believes there is an increased chance for "outright acquisition." Pantginis reiterates a Buy rating and $22 price target on the shares.
News For CPXX From the Last 2 Days
There are no results for your query CPXX